Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats migraine with or without aura. Sold as Reyvow. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Lasmiditan Succinate (sold as Reyvow), first approved Oct 11, 2019, with 0 new uses approved and 0 published complete response letters.
First approved: Oct 11, 2019
Applications: 1
New uses approved: 0
Complete response letters: 0
Medicare spending, 2025: $10.3M
First approved in the EU: Aug 17, 2022
First approved in Japan: Jan 20, 2022
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Product
Part
Spending, 2025
Change
Beneficiaries
Reyvow
Part D
$10.3M
+6%
3,175
What Pharmacies Pay
Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change
REYVOW 100 MG TABLET: $88.77 per unitBrand · 0% in a year
REYVOW 50 MG TABLET: $88.70 per unitBrand · 0% in a year
Approvals in the EU (EMA)
First approved in the EU 34 months after the US. Centrally authorised medicines, matched by ingredient; see all EU approvals
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
